1. [1] International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation: 2019.

2. [2] Khodaeian M, Enayati S, Tabatabaei-Malazy O, Amoli MM. Association between genetic variants and diabetes mellitus in Iranian populations: a systematic review of observational studies. J Diabetes Res 2015; 2015: 585917. [DOI:10.1155/2015/585917] [PMID] [PMCID]

3. [3] Sarbakhsh P, Namdari M, Mehrabi Y, Zayeri F, Daneshpour M. Association of polymorphisms and other risk factors with cholesterol level over time using logic random effect model: Tehran Lipid and Glucose Study. Koomesh 2015; 16: 193-201. (Persian).

4. [4] Campos C. Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae. Postgrad Med 2012; 124: 90-97. [DOI:10.3810/pgm.2012.11.2615] [PMID]

5. [5] Tabatabaei-Malazy O, Nikfar S, Larijani B, Abdollahi M. Drugs for the treatment of pediatric type 2 diabetes mellitus and related co-morbidities. Exp Opin Pharmacother 2016; 17: 2449-2460. [DOI:10.1080/14656566.2016.1258057] [PMID]

6. [6] Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013; 56: 973-984. [DOI:10.1007/s00125-013-2856-6] [PMID] [PMCID]

7. [7] Lang VY, Fatehi M, Light PE. Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A. Pharmacogenet Genom 2012; 22: 206-214. [DOI:10.1097/FPC.0b013e32835001e7] [PMID]

8. [8] Hamming KS, Soliman D, Matemisz LC, Niazi O, Lang Y, Gloyn AL, et al. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes Care 2009; 58: 2419-2424. [DOI:10.2337/db09-0143] [PMID] [PMCID]

9. [9] Sokolova EA, Bondar IA, Shabelnikova OY, Pyankova OV, Filipenko ML. Replication of KCNJ11 (p.E23K) and ABCC8 (p.S1369A) association in Russian diabetes mellitus 2 type cohort and meta-analysis. PLoS One 2015; 10: e0124662. [DOI:10.1371/journal.pone.0124662] [PMID] [PMCID]

10. [10] Castelan-Martinez OD, Hoyo-Vadillo C, Bazan-Soto TB, Cruz M, Tesoro-Cruz E, Valladares-Salgado A. CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide. J Clin Pharm Ther 2018; 43: 768-774. [DOI:10.1111/jcpt.12710] [PMID]

11. [11] American Diabetes Association. Approaches to glycemic treatment. Diabetes Care 2016; 39: S52-S59. [DOI:10.2337/dc16-S010] [PMID]

12. [12] Mohan V, Khunti K, Chan SP, Filho FF, Tran NQ, Ramaiya K, et al. Management of type 2 diabetes in developing countries: balancing optimal glycaemic control and outcomes with affordability and accessibility to treatment. Diabetes Ther 2020; 11: 15-35. [DOI:10.1007/s13300-019-00733-9] [PMID] [PMCID]

13. [13] Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-754. [DOI:10.2337/diacare.15.6.737] [PMID]

14. [14] Wright AD, Cull CA, Macleod KM, Holman RR. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications 2006; 20: 395-401. [DOI:10.1016/j.jdiacomp.2005.08.010] [PMID]

15. [15] Rogowski W, Payne K, Schnell-Inderst P, Manca A, Rochau U, Jahn B, et al. Concepts of 'Personalization' in personalized medicine: implications for economic evaluation. Pharmaco Economics 2014; 33: 49-59. [DOI:10.1007/s40273-014-0211-5] [PMID] [PMCID]

16. [16] Holstein A, Beil W, Kovacs P. CYP2C metabolism of oral antidiabetic drugs-impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Exp Opin Drug Metab Toxicol 2012; 8: 1549-1563. [DOI:10.1517/17425255.2012.722619] [PMID]

17. [17] Klen J, Dolzan V, Janez A. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. Eur J Clin Pharmacol 2014; 70: 421-428. [DOI:10.1007/s00228-014-1641-x] [PMID]

18. [18] Nikolac N, Simundic AM, Katalinic D, Topic E, Cipak A, Zjacic RV. Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms. Arch Med Res 2009; 40: 387-392. [DOI:10.1016/j.arcmed.2009.06.006] [PMID]

19. [19] Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney A, McCarthy MI, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007; 56: 2178-2182. [DOI:10.2337/db07-0440] [PMID]

20. [20] Ren Q, Han X, Ren J, Liu X, Ji L. Influence of the SLCO1B3 gene on sulfonylurea failure in patients with type 2 diabetes in China. Exp Clin Endocrinol Diabetes 2017; 125: 449-453. [DOI:10.1055/s-0043-103968] [PMID]

21. [21] Ren Q, Xiao D, Han XY, Edwards SL, Wang HQ, Tang Y, et al. Genetic and clinical predictive factors of sulfonylurea failure in patients with type 2 diabetes. Diabetes Technol Ther 2016; 18: 586-593. [DOI:10.1089/dia.2015.0427] [PMID]

22. [22] Ren Q, Han X, Zhang S, Cai X, Ji L. Combined influence of genetic variants and gene-gene interaction on sulfonylurea efficacy in type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2016; 124: 157-162. [DOI:10.1055/s-0035-1564161] [PMID]

23. [23] Ren Q, Han X, Tang Y, Zhang X, Zou X, Cai X, et al. Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China. Diabetologia 2014; 57: 746-753. [DOI:10.1007/s00125-013-3146-z] [PMID]

24. [24] Salam RFA, Zeyada R, Osman NA. Effect of CYP2C9 gene polymorphisms on response to treatment with sulfonylureas in a cohort of Egyptian type 2 diabetes mellitus patients. Comp Clin Pathol 2014; 23: 341-346. [DOI:10.1007/s00580-012-1620-5]

25. [25] Surendiran A, Pradhan SC, Agrawal A, Subrahmanyam DK, Rajan S, Anichavezhi D, et al. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol 2011; 67: 797-801. [DOI:10.1007/s00228-011-1013-8] [PMID]

26. [26] Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 2334-2339. [DOI:10.1210/jc.2005-2323] [PMID]

27. [27] Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 2004; 27: 1394-1398. [DOI:10.2337/diacare.27.6.1394] [PMID]